Signature Diagnostics announces a Clinical Research Collaboration with OncoMethylome Sciences
(PresseBox) (Potsdam, )Signature Diagnostics announces today that it has entered into a Clinical Research Collaboration in the field of colorectal cancer (CRC) with OncoMethylome Sciences to make available its clinical CRC platform for the development and validation of new molecular diagnostics. OncoMethylome Sciences is a public diagnostic company with offices in Liege, Leuven (Belgium), Amsterdam (the Netherlands) and Durham (NC; USA).
Starting immediately Signature Diagnostics will provide OncoMethylome Sciences with prospective tissue samples including tumor samples, plasma and stool samples as well as associated clinical data from CRC patients from all four stages of the disease.
Prof. André Rosenthal, Chief Executive Officer of Signature Diagnostics, states: "We are pleased that OncoMethylome Sciences has recognized the value of our clinical technology platform and our capability to run large multi-center prospective diagnostic trials within Germany. I am convinced that our collaboration will accelerate the validation and development of novel diagnostic products both at OncoMethylome Sciences and Signature Diagnostics. Prospective tissue sample collections are an essential component of the development of novel genomics-based diagnostics and we are excited to be able to collaborate with OncoMethylome Sciences in this strategic field." Financial figures are not disclosed.
Signature Diagnostics AG Hermannswerder 20 A D-14473Potsdam